Hotgen's invested company SGC001's innovative drug Phase Ib clinical trial has obtained positive preliminary results
Hotgen announced that its affiliated company ShunJing Pharmaceutical's innovative drug SGC001 has achieved positive preliminary results in Phase Ib clinical research. The study shows that in patients with anterior ST-segment elevation myocardial infarction receiving PCI treatment, SGC001 demonstrated an effective trend in myocardial protection in the 600mg and 900mg dosage groups compared to the placebo group, with a significant reduction in the percentage of myocardial infarction area (IS%) and a shorter time for high-sensitivity cardiac troponin I and high-sensitivity C-reactive protein to return to normal. The project will continue to advance according to the clinical trial protocol
According to the announcement from Zhitong Finance APP, Hotgen (688068.SH) reported that it has received a report from its affiliated company Beijing ShunJing Biomedical Technology Co., Ltd. (referred to as "ShunJing Pharma") regarding the positive preliminary results of the Phase Ib clinical study for its independently developed innovative drug SGC001 injection.
The preliminary efficacy results indicate that in patients with anterior ST-segment elevation myocardial infarction who received percutaneous coronary intervention (PCI) treatment in China, SGC001 showed effective trends in myocardial protection at both 600mg and 900mg dosage groups compared to the placebo group, as evidenced by a reduction in the percentage of myocardial infarction area (IS%), and a shorter time required for high-sensitivity cardiac troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels. Compared to the placebo group, there was a trend of increasing efficacy with increasing dosage, with the median percentage of myocardial infarction area reduced by 20.5% and 38.1% in the medium and high dosage groups, respectively. The project will continue to carry out clinical work according to the clinical trial protocol
